Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix BioTherapeutics Inc.    PLX

Delayed Quote. Delayed  - 04/29 09:58:12 pm
0.8251 USD   -1.53%
03/08 Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Resul..
03/03 Protalix BioTherapeutics Presents Positive Six and Twelve Month I..
02/22 Protalix BioTherapeutics to Participate in the SunTrust Robinson ..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
04/25/2016 04/26/2016 04/27/2016 04/28/2016 04/29/2016 Date
0.85(c) 0.87(c) 0.8299(c) 0.8379(c) 0.8251(c) Last
76 015 19 930 43 723 33 339 122 199 Volume
-1.23% +2.35% -4.61% +0.96% -1.53% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales 2013 5,23x
Capi. / Sales 2014 2,30x
Capitalization 82,4 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix BioTherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
04/08 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
04/01 PROTALIX BIOTHERAPEUTICS : Amendments to Articles of Inc. or Bylaws; Change in F..
03/08 PROTALIX BIOTHERAPEUTICS : Results of Operations and Financial Condition (form 8..
03/08 Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provi..
03/03 PROTALIX BIOTHERAPEUTICS : Other Events, Financial Statements and Exhibits (form..
03/03 Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clini..
02/22 Protalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orp..
01/04 PROTALIX BIOTHERAPEUTICS : Shareholder Director Nominations (form 8-K)
More news
Sector news : Biotechnology & Medical Research - NEC
04/29 SANOFI : offers to buy Medivation for $9.3bn
04/29 SANOFI : France's Sanofi makes $9.3 billion bid for US cancer drug giant
04/29DJSanofi Seeks Talks With Medivation Over $9.3 Billion Offer -- 2nd Update
More sector news : Biotechnology & Medical Research - NEC
Comments 
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix BioTherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions